Stevens Capital Management LP Takes $218,000 Position in Solventum Corporation $SOLV

Stevens Capital Management LP purchased a new stake in Solventum Corporation (NYSE:SOLV) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,876 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Strengthening Families & Communities LLC lifted its position in shares of Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after acquiring an additional 260 shares during the period. Barrett & Company Inc. lifted its position in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after purchasing an additional 268 shares during the period. IMG Wealth Management Inc. bought a new stake in Solventum during the second quarter worth about $31,000. MTM Investment Management LLC bought a new position in Solventum in the 2nd quarter valued at about $40,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after buying an additional 352 shares in the last quarter.

Solventum Price Performance

Solventum stock opened at $82.93 on Monday. The stock’s 50 day moving average is $72.68 and its 200 day moving average is $73.18. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The firm has a market cap of $14.38 billion, a P/E ratio of 9.55, a P/E/G ratio of 8.75 and a beta of 0.49. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the prior year, the firm posted $1.64 EPS. The company’s revenue for the quarter was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several analyst reports. Piper Sandler increased their price target on shares of Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Wells Fargo & Company boosted their target price on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solventum has an average rating of “Hold” and an average price target of $85.56.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.